ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0927

Review of 167,990 Same Day RAPID3, CDAI Scores for 61,312 Patients Receiving DMARD Treatment for Rheumatoid Arthritis; Evaluations of Disease Assessments and Treatment Discontinuation

Nehad Soloman1, Kent Kwas Huston2, Jasvinder singh3, Simon Helfgott4, Andrew Frick5, Scott Milligan5 and Colin Edgerton6, 1Arizona Arthritis & Rheumatology Associates, P.C., Peoria, AZ, 2Kansas City Physician Partners Center for Rheumatic Disease, Kansas City, MO, 3University of Alabama at Birmingham, Birmingham, AL, 4Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 5Trio Health, Louisville, CO, 6Articularis Healthcare, Sullivans Island, SC

Meeting: ACR Convergence 2022

Keywords: Disease-Modifying Antirheumatic Drugs (Dmards), Patient reported outcomes, rheumatoid arthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2022

Title: RA – Treatment Poster II

Session Type: Poster Session B

Session Time: 9:00AM-10:30AM

Background/Purpose: Treatment efficacy for rheumatoid arthritis is often measured through disease assessments containing subjective input from the provider, the patient, or both. Here we compare scores from same-day CDAI and RAPID3 during treatment and at treatment discontinuation, to evaluate whether these disease assessments are aligned and are indicative of disease management.

Methods: Data are specific to patients in care by the American Rheumatology Network, and reside in PIONEER Rheumatology, an enhanced database combining fielded EMR data with extracted information from open text (office visits, infusions logs, and provider-patient communications). Study population: 61,312 patients with RA receiving conventional synthetic, targeted synthetic (ts), and/or biologic (b) DMARDs between 2014 to 2021 and with same day CDAI and RAPID3 scores. Total observations: 167,990 disease assessment scores, 83,995 patient-dates. Analyses conducted using R v.3.6: Spearman’s rho (score classifications), Pearson correlation (numeric scores), and Cohen’s weighted Kappa (score classification). Discontinuation analyses were limited to ts/bDMARD episodes and scores considered were closest to but between -90 to +14 days of discontinuation. Rapid3 and CDAI were split into low/remission, moderate, and severe disease activity.

Results: A moderate agreement between same day CDAI and RAPID3 scores was suggested by Cohen’s Weighted Kappa (0.42) and Spearman’s rho (0.49). By disease severity classifications, a greater proportion of RAPID3 results indicated severe disease (35.8%; 30,057/83,995) v. CDAI (13.8%; 11,618/83,995; p< 0.001). Of the severe results by RAPID3, 25.6% (7683/30,057) were recorded as near-remission/low activity by CDAI. Conversely, 15.6% (1,818/11,618) of CDAI results indicating severe disease were classified as near-remission/low by RAPID3. In subset analyses examining scores at ts/bDMARD discontinuation (n=3600 drug episodes), 53.9% (1,939/3,600) had an accompanying RAPID3 result indicating severe disease compared to 31.6% by CDAI (1,136/3,600; p< 0.001). Of the 3,600 episodes, 47% (1,692) discontinued due to lack or loss of efficacy, as documented in visit notes; the remainder discontinued for non-clinical reasons and/or conditions arising from treatment, disease, or existing patient burden. For ts/bDMARD episodes discontinued for efficacy reasons, 19.6% (332/1,692) had an accompanying RAPID3 result indicating near-remission/low activity and 21.1% (356/1,692) indicated near-remission/low activity by CDAI (p=0.273). Scatter plots of individual scores are provided in the FIGURE.

Conclusion: A moderate correlation was observed between RAPID3, a patient-based disease assessment, and CDAI, a predominantly physician-based disease assessment. However, considerable discord was observed for ~10% of assessments, calling into question which assessment is a better indicator of disease management. Moreover, 20% of ts/bDMARD episodes that discontinued due to lack or loss of efficacy had near-remission/low disease activity by either RAPID3 or CDAI. These data suggest that some patient-important outcomes are not reflected in these assessments.

Supporting image 1


Disclosures: N. Soloman, AbbVie/Abbott, Horizon, Janssen, Amgen, GlaxoSmithKlein(GSK), AstraZeneca; K. Huston, None; J. singh, Schipher, Crealta/Horizon, Medisys, Fidia, PK Med, Two Labs Inc., Adept Field Solutions, Clinical Care Options, Clearview Healthcare Partners, Putnam Associates, Focus Forward, Navigant Consulting, Spherix, MedIQ, Jupiter Life Science, UBM LLC, Trio Health, Medscape, WebMD, Practice Point Communications, National Institutes of Health, American College of Rheumatology, Zimmer Biomet Holdings, Intuitive Surgical Inc./Philips Electronics North America, TPT Global Tech, Vaxart Pharmaceuticals, Atyu Biopharma, Adaptimmune Therapeutics, GeoVax Labs, Pieris Pharmaceuticals, Enzolytics Inc., Seres Therapeutics, Tonix Pharmaceuticals Holding Corp, Charlotte's Web Holdings, Inc., Amarin, Viking, Moderna Pharmaceuticals, Simply Speaking, Outcomes Measures in Rheumatology (OMERACT), FDA Arthritis Advisory Committee, Veterans Affairs Rheumatology Field Advisory Board (FAB), University of Alabama at Birmingham (UAB) Cochrane Musculoskeletal Group Satellite Center on Network Meta-analysis; S. Helfgott, Abbott Ltd., Genentech; A. Frick, Trio Health Analytics; S. Milligan, AbbVie/Abbott, AstraZeneca, GlaxoSmithKlein(GSK), UCB; C. Edgerton, Novartis, Boehringer-Ingelheim.

To cite this abstract in AMA style:

Soloman N, Huston K, singh J, Helfgott S, Frick A, Milligan S, Edgerton C. Review of 167,990 Same Day RAPID3, CDAI Scores for 61,312 Patients Receiving DMARD Treatment for Rheumatoid Arthritis; Evaluations of Disease Assessments and Treatment Discontinuation [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/review-of-167990-same-day-rapid3-cdai-scores-for-61312-patients-receiving-dmard-treatment-for-rheumatoid-arthritis-evaluations-of-disease-assessments-and-treatment-discontinuation/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/review-of-167990-same-day-rapid3-cdai-scores-for-61312-patients-receiving-dmard-treatment-for-rheumatoid-arthritis-evaluations-of-disease-assessments-and-treatment-discontinuation/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology